[1] Hayashi PH,Di Bisceglie AM. The progression of hepatitis B-and C-infections to chronic liver disease and hepatocellular carcinoma:epidemiology and pathogenesis[J]. Med Clin North Am,2005,89(2):371-389.
[2] Lavanchy D.Hepatitis B virus epidemiology,disease burden,treatment,and current and emerging prevention and control measures[J].J Viral Hepat,2004,11(2):97-107.
[3] 李赫伦.抗纤协定方联合恩替卡韦治疗血瘀气血两虚乙肝肝纤维化的临床观察[D].沈阳:辽宁中医药大学,2015.
[4] 陈简.聚乙二醇干扰素治疗拉米夫定耐药慢乙肝患者中耐药毒株动态变化及其与疗效的关系[D].广州:南方医科大学,2015.
[5] 陈爱萍.核苷(酸)类似物联合干扰素治疗144例慢性乙肝患者的药效评估[J].海南医学院学报,2013,19(2):209-211.
[6] 陈军,杨发周,鲁磊.解毒软肝片防治鸭乙型肝炎肝纤维化的实验研究[J].中西医结合肝病杂志,2014,24(6):354-356.
[7] 沈海容.红背叶根提取物抗乙肝病毒和抗肝损伤的药效学研究[D].广州:南方医科大学,2014.
[8] 张传涛,廖志航,陈东辉,等.乙型肝炎病毒感染细胞与动物模型研究现状[J].军医进修学院学报,2010,7(10):1036-1038.
[9] 耿淼,王建华,陈红艳,等.金丝桃苷对鸭乙肝病毒cccDNA清除及免疫调节作用探讨[J].药学学报,2009,4(12):1440-1444.
[10] 陈银苹,吴爱萍,余亮科.组合模型对乙肝发病趋势的预测研究[J].解放军医学杂志,2014,7(1):52-56.
[11] 张军楠,邵杰,梁争论.Ⅰ型干扰素免疫应答作用机制研究进展[J].微生物学免疫学进展,2014,8(3):54-58.
[12] Cao J,Ou X,Zhu D,et al.The 2A2 protein of Duck hepatitis A virus type 1 induces apoptosis in primary cell culture[J].Virus Genes,2016,52(6):780-788.
[13] 黄东彬,管静.龙葵承气汤对原发性肝癌患者TACE术后肝纤维化指标及免疫功能的影响[J].新中医,2016,48(5):211-213.
[14] 陈宏超.鳖甲软肝丸联合恩替卡韦片治疗乙肝肝硬化临床疗效观察[J].中国现代药物应用,2015,9(24):103-104.
[15] Thermet A,Buronfosse T,Werle-Lapostolle B,et al.DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection[J].J Gen Virol,2008,89(Pt 5):1192-1201.
[16] Chang L,Lan T,Wu L,et al.The association between three IL-6 polymorphisms and HBV-related liver diseases:a meta-analysis[J].Int J Clin Exp Med,2015,8(10):17036-17045.
[17] Saxena R,Chawla YK,Verma I,et al.IFN-γ (+874) and not TNF-α (-308) is associated with HBV-HCC risk in India[J].Mol Cell Biochem,2014,385(1/2):297-307.
[18] 王晓丽,王永明,朱万光,等.干扰素研究进展[J].动物医学进展,2008,29(12):60-63. |